During testimony before a congressional hearing on drug prices this month, Dr. Aaron Lord (left), a patient advocate and AIDS activist, publicly challenged Daniel O’Day, CEO of Gilead Sciences (right), to lower the price of Gilead’s HIV prevention drug Truvada.

During testimony before a congressional hearing on drug prices this month, Dr. Aaron Lord (left), a patient advocate and AIDS activist, publicly challenged Daniel O’Day, CEO of Gilead Sciences (right), to lower the price of Gilead’s HIV prevention drug Truvada